Ergogenic Properties of Magnesium Supplementation

Exercise Performance Clinical Trial

Official title:

Ergogenic Properties of Magnesium Supplementation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05282693
• Other study ID #: 1659
• Status: Completed
• Phase: N/A
• Start date: December 17, 2021
• Est. completion date: February 28, 2024

Study information

• Verified date: May 2024
• Source: Colorado State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the proposed project is to determine if short-term dietary supplementation of magnesium will improve performance during a series of lab-based exercise tests, will favorably modify the gut-microbiota, and will augment skeletal muscle mitochondrial function.

Description:

Magnesium is the fourth most abundant mineral in the human body. It is critical to day-to-day physiological function including the regulation of metabolism, cardiovascular function, immune function, and the operation of the nervous system. In light of its important role in physiology, dietary supplementation of magnesium has been purported to improve athletic performance, although the precise mechanism is unclear. The foci of the proposed study is the ergogenic effects of magnesium, its potential influence on gut health, and its potential ability to improve skeletal muscle function. The investigators will be studying an athletic/competitive population of endurance-trained adults. This group is likely to be the most interested in the use of magnesium to enhance athletic performance. Also, by only recruiting habitual exercisers, the variability between participants is likely to be reduced compared with if the investigators had also recruited people who are usually sedentary.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: February 28, 2024
• Est. primary completion date: February 28, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Competitive cyclists

• Adult males and females (18 - 40 years, inclusive) who have exercised a minimum of 5 days per week, for a minimum of 30-minutes/session, during the previous 2 years.

• Maximal oxygen uptake (VO2max) satisfying the minimum criteria for "Good" (sex- and age-adjusted) as defined by the American College of Sports Medicine.

Exclusion Criteria:

• Identification of a contra-indication to exercise during a 12-lead exercise stress test

• Use of a magnesium supplement within the previous 4 weeks

• Pregnancy or breast-feeding

• Unable to perform vigorous exercise

• History (previous diagnosis) of kidney disease

• Use of laxatives, Zinc, diuretics, proton pump inhibitors, over the counter agents such as certain heartburn and GI/gut treatments (laxatives) which contain magnesium, Zinc or other high dose cations which reduce absorption of Magnesium

Related Conditions & MeSH terms

• Exercise Performance
• Mitochondrial Function

Intervention

Dietary Supplement:
• ReMag
300 mg of ReMag dissolved in lemon flavor liquid
• Placebo
Lemon flavored liquid

Locations

Country	Name	City	State
United States	Colorado State University, Dept. of Health and Exercise Science	Fort Collins	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
Christopher Bell

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of completion of time trial to placebo	Amount of time it takes to cycle 10 kilometers	After 9 days of intervention
Primary	Comparison of power output to placebo	Cycling for 30 seconds	After 9 days of intervention
Primary	Comparison of indirect Calorimetry (VO2max) to placebo	During a standard stress test VO2 max will be measured	After 8 days of intervention
Primary	Comparison of lactate threshold to placebo	During a standard stress test lactate threshold will be measured	After 8 days of intervention
Primary	Comparison of Mitochondrial Function to placebo	Assessed via high-resolution mitochondrial respirometry in permeabilized skeletal muscle.	After 8 days of intervention
Primary	Comparison of Shannon and Faith's microbiota diversity scores in feces to placebo	Assessed via 16s ribosomal ribonucleic acid microbial profiling	After 9 days of intervention,
Primary	Calculation and ordination of B-diversity scores for all fecal samples to assess clustering	Assessed via 16s ribosomal ribonucleic acid microbial profiling	After 9 days of intervention
Primary	Determination of differentially abundant microbiota in feces of collected during treatment compared to placebo	Assessed via 16s ribosomal ribonucleic acid microbial profiling	After 9 days of intervention
Primary	Comparison of abundant microbiota to markers in feces to placebo	Assessed via Linear discriminant analysis Effect Size algorithm	After 9 days of intervention
Primary	Comparison Human Granulocyte Macrophage Colony-Stimulating Factor to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interferon gamma to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 1 beta to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 2 to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 4 to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 5 to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 6 to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 7 to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 8 to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 10 to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 12 (p70) to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison interleukin 13 to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison Tumor Necrosis Factor alpha to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention
Primary	Comparison High-sensitivity C-reactive protein to placebo	Assessed via 13-plex human T-cell cytokine panel	After 9 days of intervention